Overexpression of DDR1 contributes to gastric cancer progression by inhibiting the Hippo pathway

Abstract

Gastric cancer (GC) is a prevalent and devastating disease with a poor prognosis. The lack of biomarkers for early detection and effective targeted therapeutics for GC patients represents two major challenges. Through isobaric tags for relative and absolute quantitation (iTRAQ) coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS) phosphoproteomic analysis of 14 GC and gastric epithelial cell lines, we discovered the discoidin domain receptor tyrosine kinase 1 (DDR1) as a top potential drug target out of 40 tyrosine kinases detected along with over 1000 phosphoproteins profiled. The DDR1 protein and mRNA levels were upregulated in GC cells concurrent with DDR1 gene amplification. Immunohistochemistry staining of more than 200 clinical samples revealed that DDR1 was overexpressed in approximately 41% and 48% of the intestinal and diffuse types of GC cases, respectively, compared with only 3.5% in normal tissues. Higher DDR1 expression was associated with poor prognosis. In cellular models, DDR1 overexpression led to accelerated proliferation, invasion, and malignant transformation, putatively via inhibition of the Hippo pathway and consequent activation of YAP-TEAD target gene expression. Notably, DDR1-overexpressing GC cells exhibited high vulnerability to selective DDR1 inhibitors. The present study provides preclinical support for the application of DDR1-selective inhibitors in DDR1-overexpressing GC.

Keywords

iTRAQ / gastric cancer / DDR1 / 7rh / Hippo pathway / phosphoproteomic analysis

Fundings

The current study was supported by the National Natural Science Foundation of China (Grant No. 32170738) and the National Medical Research Council of Singapore (Grant No. NMRC/CBRG/ 0013/2012).

Acknowledgments

None.

References

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. doi: 10.3322/caac.21834

[2] Leung WK, Wu M, Kakugawa Y, et al. Screening for gastric cancer in Asia: Current evidence and practice[J]. Lancet Oncol, 2008, 9(3): 279-287. doi: 10.1016/S1470-2045(08)70072-X

[3] Blume-Jensen P, Hunter T. Oncogenic kinase signalling[J]. Nature, 2001, 411(6835): 355-365. doi: 10.1038/35077225

[4] Johnson JD, Edman JC, Rutter WJ. A receptor tyrosine kinase found in breast carcinoma cells has an extracellular discoidin I-like domain[J]. Proc Natl Acad Sci U S A, 1993, 90(12): 5677-5681. doi: 10.1073/pnas.90.12.5677

[5] Xu H, Raynal N, Stathopoulos S, et al. Collagen binding specificity of the discoidin domain receptors: Binding sites on collagens Ⅱ and Ⅲ and molecular determinants for collagen Ⅳ recognition by DDR1[J]. Matrix Biol, 2011, 30(1): 16-26. doi: 10.1016/j.matbio.2010.10.004

[6] Wei Z, Li J, Zhong L, et al. DDR1 drives malignant progression of gastric cancer by suppressing HIF-1α ubiquitination and degradation[J]. Adv Sci (Weinh), 2024, 11(35): e2308395. doi: 10.1002/advs.202308395

[7] Wang J, Wang L, Qiang W, et al. The role of DDR1 in cancer and the progress of its selective inhibitors[J]. Bioorg Chem, 2025, 154: 108018. doi: 10.1016/j.bioorg.2024.108018

[8] Wu D, Ding Z, Lu T, et al. DDR1-targeted therapies: Current limitations and future potential[J]. Drug Discov Today, 2024, 29(5): 103975. doi: 10.1016/j.drudis.2024.103975

[9] Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer[J]. Cancer Discov, 2011, 1(1): 78-89. doi: 10.1158/2159-8274.CD-11-0005

[10] Gao M, Duan L, Luo J, et al. Discovery and optimization of 3-(2-(pyrazolo[1, 5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors[J]. J Med Chem, 2013, 56(8): 3281-3295. doi: 10.1021/jm301824k

[11] Kim HG, Tan L, Weisberg EL, et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor[J]. ACS Chem Biol, 2013, 8(10): 2145-2150. doi: 10.1021/cb400430t

[12] Elkamhawy A, Park JE, Cho NC, et al. Discovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase: Cell line-based assay, kinase panel, molecular docking, and toxicity studies[J]. J Enzyme Inhib Med Chem, 2016, 31(1): 158-166. doi: 10.3109/14756366.2015.1004057

[13] Cao Z, An L, Han Y, et al. The Hippo signaling pathway in gastric cancer[J]. Acta Biochim Biophys Sin (Shanghai), 2023, 55(6): 893-903. doi: 10.3724/abbs.2023038

[14] Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer[J]. Cell, 2007, 131(6): 1190-1203. doi: 10.1016/j.cell.2007.11.025

[15] Lim SK, Lu SY, Kang SA, et al. Wnt signaling promotes breast cancer by blocking ITCH-mediated degradation of YAP/TAZ transcriptional coactivator WBP2[J]. Cancer Res, 2016, 76(21): 6278-6289. doi: 10.1158/0008-5472.CAN-15-3537

[16] Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents[J]. Mol Cell Proteomics, 2004, 3(12): 1154-1169. doi: 10.1074/mcp.M400129-MCP200

[17] Hum M, Tan HJ, Yang Y, et al. WBP2 promotes gastric cancer cell migration via novel targeting of LATS2 kinase in the Hippo tumor suppressor pathway[J]. FASEB J, 2021, 35(2): e21290. doi: 10.1096/fj.202000393R

[18] Wang S, Fu Y, Kuerban K, et al. Discoidin domain receptor 1 is a potential target correlated with tumor invasion and immune infiltration in gastric cancer[J]. Front Immunol, 2022, 13: 933165. doi: 10.3389/fimmu.2022.933165

[19] Szász AM, Lánczky A, Nagy Á, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1, 065 patients[J]. Oncotarget, 2016, 7(31): 49322-49333. doi: 10.18632/oncotarget.10337

[20] Wei J, Huang K, Chen Z, et al. Characterization of glycolysis-associated molecules in the tumor microenvironment revealed by pan-cancer tissues and lung cancer single cell data[J]. Cancers (Basel), 2020, 12(7): 1788. doi: 10.3390/cancers12071788

[21] Xiong Y, Zhang X, Zhu J, et al. Collagen I-DDR1 signaling promotes hepatocellular carcinoma cell stemness via Hippo signaling repression[J]. Cell Death Differ, 2023, 30(7): 1648-1665. doi: 10.1038/s41418-023-01166-5

[22] Valiathan RR, Marco M, Leitinger B, et al. Discoidin domain receptor tyrosine kinases: New players in cancer progression[J]. Cancer Metastasis Rev, 2012, 31(1-2): 295-321. doi: 10.1007/s10555-012-9346-z

[23] Zheng Y, Pan D. The Hippo signaling pathway in development and disease[J]. Dev Cell, 2019, 50(3): 264-282. doi: 10.1016/j.devcel.2019.06.003

[24] Wang Y, Xu X, Maglic D, et al. Comprehensive molecular characterization of the Hippo signaling pathway in cancer[J]. Cell Rep, 2018, 25(5): 1304-1317.e5.

[25] Lemeer S, Bluwstein A, Wu Z, et al. Phosphotyrosine mediated protein interactions of the discoidin domain receptor 1[J]. J Proteomics, 2012, 75(12): 3465-3477. doi: 10.1016/j.jprot.2011.10.007

[26] Ongusaha PP, Kim JI, Fang L, et al. p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop[J]. EMBO J, 2003, 22(6): 1289-1301. doi: 10.1093/emboj/cdg129

[27] Fan R, Kim NG, Gumbiner BM. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1[J]. Proc Natl Acad Sci U S A, 2013, 110(7): 2569-2574. doi: 10.1073/pnas.1216462110

[28] Vogel W, Gish GD, Alves F, et al. The discoidin domain receptor tyrosine kinases are activated by collagen[J]. Mol Cell, 1997, 1(1): 13-23. doi: 10.1016/S1097-2765(00)80003-9

[29] Wellcome Sanger Institute. Cosmic: Catalogue of Somatic Mutations in Cancer[EB/OL]. [2025-04-10]. https://cancer.sanger.ac.uk/cosmic/login.

[30] Ford CE, Lau SK, Zhu C, et al. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma[J]. Br J Cancer, 2007, 96(5): 808-814. doi: 10.1038/sj.bjc.6603614

[31] Shintani Y, Fukumoto Y, Chaika N, et al. Collagen Ⅰ-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1[J]. J Cell Biol, 2008, 180(6): 1277-1289. doi: 10.1083/jcb.200708137

[32] Wang CZ, Su HW, Hsu YC, et al. A discoidin domain receptor 1/SHP-2 signaling complex inhibits α2β1-integrin-mediated signal transducers and activators of transcription 1/3 activation and cell migration[J]. Mol Biol Cell, 2006, 17(6): 2839-2852. doi: 10.1091/mbc.e05-11-1068

[33] Claude-Taupin A, Isnard P, Bagattin A, et al. The AMPK-Sirtuin 1-YAP axis is regulated by fluid flow intensity and controls autophagy flux in kidney epithelial cells[J]. Nat Commun, 2023, 14(1): 8056. doi: 10.1038/s41467-023-43775-1

[34] Dai W, Liu S, Wang S, et al. Activation of transmembrane receptor tyrosine kinase DDR1-STAT3 cascade by extracellular matrix remodeling promotes liver metastatic colonization in uveal melanoma[J]. Sig Transduct Target Ther, 2021, 6(1): 176. doi: 10.1038/s41392-021-00563-x